organogenesis.com (ORGO): Price-to-Projected Revenue Ratio

ORGO (Organogenesis) - company brandmark

Organogenesis Holdings revenue dynamics are currently adapting to updated government reimbursements, as evidenced by the forward P/S ratio. The 0.30 level reflects the current value of this indicator. Growth is driven by leadership in tissue bioengineering for surgeons. Unique patents for treating complex wounds enable premium pricing, creating a local monopoly within the medical field.

ORGO organogenesis.com: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/16/2026

ORGO (organogenesis.com): analytical breakdowns and indicator data

- stock exchange capitalization data:
Fundamental company valuation:organogenesis.com ORGO
Product sample of Organogenesis Holdings

Organogenesis Holdings (ORGO) leverages unique patents and insurance codes to create a high barrier to entry for competitors within the regenerative medicine segment. The estimated forward P/S ratio quantifies this advantage by comparing the company's current market value with its projected annual revenue. This metric enables an assessment of the value of future earnings, neutralizing the time lags associated with standard reporting and accounting for cash flow gap risks. Analyzing the trend of the estimated forward P/S helps investors timely identify whether the asset is overbought or if there is a critical increase in the debt load.

Competitor analysis

Forward P/S Multiple HCA (HCA Healthcare, Inc.)|Price to Expected Revenue Ratio THC (Tenet Healthcare)|FMS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio solventum.com|EHC: Forward P/S Multiple|UHS - Market Cap to Expected Sales Ratio|DVA (DaVita Corp) - Forward P/S Multiple|RDNT: Forward Price to Sales|Forward P/S Multiple OPCH|SGRY (surgerypartners.com) - Forward Price to Sales|Forward P/S Multiple PINC (Premier Inc)|National Vision - Price-to-Projected Revenue Ratio|PGNY - Price-to-Projected Revenue Ratio|ARDT - Forward P/S Multiple|SEM: Forward P/S Multiple|astranahealth.com (ASTH) - Forward P/S Multiple|MD (mednax.com) - Forward P/S Multiple|Forward P/S Multiple usph.com|Forward P/S Multiple PNTG|NUTX (Nutex Health Corp) - Forward Price to Sales|Forward P/S Multiple AUNA (Auna S.A.)|SBC Medical Group Holdings Inc (SBC) - Market Cap to Future Revenue Ratio|EOLS - Price-to-Projected Revenue Ratio|Forward Price to Sales CYH (Community Health Systems Inc)|SKIN (beautyhealth.com) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue MDWD|Price-to-Projected Revenue Ratio biote Corp.|Market Cap to Future Revenue Ratio thejoint.com JYNT|Forward P/S Multiple DCGO|Forward Price-to-Revenue Multiple P3 Health PIII|Forward P/S Multiple GANX (Gain Therapeutics Inc.)|Forward P/S Multiple EUDA Health Holdings Limited EUDA|baselmedical.com - Forward P/S Multiple|CLGN: Price-to-Projected Revenue Ratio|Cuprina Holdings (Cayman) Ltd. (CUPR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Concord Medical|AMS (American Shared Hospital Services Inc) - Forward P/S Multiple|MEDIROM Corp (MRM) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ALBT|Market Cap to Expected Sales Ratio DIH Holding|Forward P/S Multiple XAGE (carmellcosmetics.com)|NIVF: Market Cap to Projected Revenue|ATIP: Forward Price-to-Revenue Multiple|CareMax Medical Group - Price to Expected Revenue Ratio|Kindly MD (KDLY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue MODV|Price-to-Projected Revenue Ratio Novo Integrated Sciences Corp|Market Cap to Future Revenue Ratio SunLink Health Systems SSY|Price-to-Projected Revenue Ratio IMAC Corp (BACK)